SAB Biotherapeutics (SABS) Receivables - Accured (2024 - 2026)
SAB Biotherapeutics (SABS) posted Receivables - Accured of $1.6 million for Q1 2026, up 68.99% on a QoQ basis from $946781.0 in Q4 2025, and up 7381.53% year-over-year from $21386.0 in Q1 2025.
SAB Biotherapeutics (SABS) Receivables - Accured (2024 - 2026) Analysis & Trends
SAB Biotherapeutics' Receivables - Accured history runs 3 years deep, the most recent figure standing at $1.6 million for Q1 2026.
- Quarterly Receivables - Accured rose 7381.53% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (up 7381.53% YoY) and the FY2025 annual result came in at $946781.0, up 1622.83% from the prior year.
- Receivables - Accured was $1.6 million for Q1 2026 at SAB Biotherapeutics, up from $946781.0 in the prior quarter.
- Across five years, Receivables - Accured topped out at $1.6 million in Q1 2026 and bottomed at $21386.0 in Q1 2025.
- A 3-year average of $462294.4 and a median of $209116.0 in 2024 frame the typical range for Receivables - Accured.
- Annual changes were most pronounced in 2025 — Receivables - Accured slumped 88.93% — and 2026, when it surged 7381.53%.
- SAB Biotherapeutics' Receivables - Accured stood at $54955.0 in 2024, then surged by 1622.83% to $946781.0 in 2025, then jumped by 68.99% to $1.6 million in 2026.
- Business Quant data shows SABS's Receivables - Accured at $1.6 million in Q1 2026, $946781.0 in Q4 2025, and $559954.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables - Accured (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | SAB Biotherapeutics | 170.64 Mn | 170.64 Mn | - | 1.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.60 Mn |
| Mar 31, 2026 | 1.60 Mn |
| Dec 31, 2025 | 946,781.00 |
| Dec 31, 2025 | 946,781.00 |
| Sep 30, 2025 | 559,954.00 |
| Sep 30, 2025 | 559,954.00 |
| Mar 31, 2025 | 21,386.00 |
| Mar 31, 2025 | 21,386.00 |
| Dec 31, 2024 | 54,955.00 |
| Dec 31, 2024 | 54,955.00 |
| Sep 30, 2024 | 97,047.00 |
| Sep 30, 2024 | 97,047.00 |
| Jun 30, 2024 | 225,000.00 |
| Jun 30, 2024 | 225,000.00 |
| Mar 31, 2024 | 193,232.00 |
| Mar 31, 2024 | 193,232.00 |